Cargando…

Combining Anti-ERBB3 Antibodies Specific for Domain I and Domain III Enhances the Anti-Tumor Activity over the Individual Monoclonal Antibodies

BACKGROUND: Inappropriate signaling through the epidermal growth factor receptor family (EGFR1/ERBB1, ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4) of receptor tyrosine kinases leads to unregulated activation of multiple downstream signaling pathways that are linked to cancer formation and progression. In...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Souza, Jimson W., Reddy, Smitha, Goldsmith, Lisa E., Shchaveleva, Irina, Marks, James D., Litwin, Samuel, Robinson, Matthew K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227695/ https://www.ncbi.nlm.nih.gov/pubmed/25386657 http://dx.doi.org/10.1371/journal.pone.0112376

Ejemplares similares

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

Novel single-domain antibodies against the EGFR domain III epitope exhibit the anti-tumor effect
por: Chen, Tao, et al.
Publicado: (2020)

A Murine Monoclonal Antibody that Recognizes an Extracellular Domain of the Human c‐erbB‐2 Protooncogene Product
por: Masuko, Takashi, et al.
Publicado: (1989)

In vitro Anti‐tumor Activity of Anti‐c‐erbB‐2 × Anti‐CD3ɛ Bifunctional Monoclonal Antibody
por: Sugiyama, Yoshihiro, et al.
Publicado: (1992)

Human Tumor Growth Suppression by Apoptosis Induced with Anti‐ErbB‐2 Chimeric Monoclonal Antibody
por: Sasaki, Shigeru, et al.
Publicado: (1998)

Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal antibody.
por: Ohnishi, Y., et al.
Publicado: (1995)

Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize
por: Adams, Stephen R., et al.
Publicado: (2016)

Establishment of rat anti-canine DEP domain containing 1B (DEPDC1B) monoclonal antibodies
por: IGASE, Masaya, et al.
Publicado: (2020)

Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II
por: Mazumder, Suparna, et al.
Publicado: (2020)

Novel anti-PTEN C2 domain monoclonal antibodies to analyse the expression and function of PTEN isoform variants
por: Torices, Leire, et al.
Publicado: (2023)

Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies
por: Miano, Carmen, et al.
Publicado: (2022)

Establishment of anti-mesothelioma monoclonal antibodies
por: Mizutani, Natsuko, et al.
Publicado: (2016)

In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product.
por: Tokuda, Y., et al.
Publicado: (1996)

Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein
por: Budigi, Yadunanda, et al.
Publicado: (2018)

Novel monoclonal antibodies targeting the microtubule-binding domain of human tau
por: Croft, Cara L., et al.
Publicado: (2018)

Improving the biophysical properties of anti-ricin single-domain antibodies()
por: Turner, Kendrick B., et al.
Publicado: (2015)

Constant domain polymorphisms influence monoclonal antibody stability and dynamics
por: Warrender, Annmaree K., et al.
Publicado: (2023)

Cyclosporin A prevents the anti-murine antibody response to a monoclonal anti-tumour antibody in rabbits.
por: Ledermann, J. A., et al.
Publicado: (1988)

Anti-T cell immunoglobulin and mucin domain-2 monoclonal antibody exacerbates collagen-induced arthritis by stimulating B cells
por: Kawamoto, Toshio, et al.
Publicado: (2011)

Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains
por: Turner, Hannah L., et al.
Publicado: (2019)

Correction: Immunotherapy of ovarian cancer with a monoclonal antibody specific for the extracellular domain of anti-Müllerian hormone receptor II
por: Mazumder, Suparna, et al.
Publicado: (2022)

Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer
por: Noto, Alessia, et al.
Publicado: (2013)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
por: Cavazzoni, Andrea, et al.
Publicado: (2012)

Anti-TRAP/SSP2 monoclonal antibodies can inhibit sporozoite infection and may enhance protection of anti-CSP monoclonal antibodies
por: Wilder, Brandon K., et al.
Publicado: (2022)

Domain unfolding of monoclonal antibody fragments revealed by non-reducing SDS-PAGE
por: Kirley, Terence L., et al.
Publicado: (2018)

Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope
por: Makabe, Koki, et al.
Publicado: (2021)

Generation and Characterization of Anti-Filovirus Nucleoprotein Monoclonal Antibodies
por: Rahim, Md Niaz, et al.
Publicado: (2019)

Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III
por: Wu, Yanling, et al.
Publicado: (2017)

A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III
por: Hu, Dan, et al.
Publicado: (2019)

Anti‐murine Antibody Response to Mouse Monoclonal Antibodies in Cancer Patients
por: Sakahara, Harumi, et al.
Publicado: (1997)

Selection and Characterization of Anti-Dengue NS1 Single Domain Antibodies
por: Shriver-Lake, Lisa C., et al.
Publicado: (2018)

Mapping two functional domains of clathrin light chains with monoclonal antibodies
Publicado: (1987)

Comparing different domains of analysis for the characterisation of N-glycans on monoclonal antibodies
por: Carillo, Sara, et al.
Publicado: (2020)

Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies
por: Liu, Shufang, et al.
Publicado: (2021)

Domain-and species-specific monoclonal antibodies recognize the Von Willebrand Factor-C domain of CCN5
por: Wei, Lan, et al.
Publicado: (2009)

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
por: Robinson, M K, et al.
Publicado: (2008)

An anti-ErbB2 fully human antibody circumvents trastuzumab resistance
por: Lu, Qiong, et al.
Publicado: (2016)

Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies
por: Zhang, Fengwen, et al.
Publicado: (2023)

The promise of anti-ErbB3 monoclonals as new cancer therapeutics
por: Aurisicchio, Luigi, et al.
Publicado: (2012)

Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies
por: Pietsch, E C, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fps1uv7f0qr86g2h72129ofcl1